Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis

Last updated: April 6, 2020
Sponsor: Hospices Civils de Lyon
Overall Status: Active - Recruiting

Phase

N/A

Condition

Memory Loss

Herpes Simplex Infections

Treatment

N/A

Clinical Study ID

NCT04339127
NMDARE-HSE
  • All Genders

Study Summary

Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate.

One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis.

The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF

  • After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF

  • Without age limit

Exclusion Criteria- No respect of inclusion criteria

Study Design

Total Participants: 12
Study Start date:
April 01, 2020
Estimated Completion Date:
October 01, 2020

Connect with a study center

  • Hospice Civils de Lyon

    Bron, 69500,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.